CY1118461T1 - Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης - Google Patents
Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασηςInfo
- Publication number
- CY1118461T1 CY1118461T1 CY20171100074T CY171100074T CY1118461T1 CY 1118461 T1 CY1118461 T1 CY 1118461T1 CY 20171100074 T CY20171100074 T CY 20171100074T CY 171100074 T CY171100074 T CY 171100074T CY 1118461 T1 CY1118461 T1 CY 1118461T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical compositions
- aromatology
- ingredients
- compositions containing
- relates
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 title 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε χαμηλής-δόσης φαρμακευτικές συνθέσεις που περιλαμβάνουν τον αναστολέα αρωματάσης 4,4'-[φθορο-(1-Η-1,2,4-τριαζολ-1-υλ)μεθυλενο]δισβενζονιτρίλιο ως το δραστικό συστατικό σε κατάλληλο φορέα. Η παρούσα εφεύρεση επίσης αφορά σε μία μέθοδο για παρασκευή αυτού και χρήση αυτού ως φάρμακα.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201261638588P | 2012-04-26 | 2012-04-26 | |
| PCT/US2012/053846 WO2013036563A1 (en) | 2011-09-08 | 2012-09-06 | Pharmaceutical compositions comprising an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118461T1 true CY1118461T1 (el) | 2017-07-12 |
Family
ID=46846026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100074T CY1118461T1 (el) | 2011-09-08 | 2017-01-18 | Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης |
| CY20171100100T CY1118499T1 (el) | 2011-09-08 | 2017-01-24 | Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100100T CY1118499T1 (el) | 2011-09-08 | 2017-01-24 | Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9295668B2 (el) |
| EP (2) | EP2753313B1 (el) |
| JP (2) | JP6280501B2 (el) |
| KR (3) | KR20140071358A (el) |
| CN (2) | CN103781476B (el) |
| AR (1) | AR087790A1 (el) |
| AU (2) | AU2012304694B2 (el) |
| BR (2) | BR112014005434B1 (el) |
| CA (2) | CA2845929C (el) |
| CL (1) | CL2014000552A1 (el) |
| CY (2) | CY1118461T1 (el) |
| DK (2) | DK2753312T3 (el) |
| ES (2) | ES2613666T3 (el) |
| HR (2) | HRP20170003T1 (el) |
| HU (2) | HUE031435T2 (el) |
| IL (1) | IL231234A (el) |
| IN (1) | IN2014DN01619A (el) |
| LT (2) | LT2753312T (el) |
| MX (2) | MX343902B (el) |
| PE (1) | PE20141584A1 (el) |
| PH (1) | PH12014500435A1 (el) |
| PL (2) | PL2753312T3 (el) |
| PT (2) | PT2753312T (el) |
| RU (2) | RU2628808C2 (el) |
| SG (2) | SG10201607503WA (el) |
| SI (2) | SI2753312T1 (el) |
| TN (1) | TN2014000059A1 (el) |
| TW (1) | TW201316987A (el) |
| UY (1) | UY34315A (el) |
| WO (2) | WO2013036563A1 (el) |
| ZA (1) | ZA201401040B (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2628808C2 (ru) * | 2011-09-08 | 2017-08-22 | Новартис Аг | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний |
| WO2015148549A1 (en) * | 2014-03-26 | 2015-10-01 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| KR102468610B1 (ko) * | 2014-07-07 | 2022-11-21 | 리코다티 아게 | 제약 투여 형태 |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (ja) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | 男性性腺機能低下症治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (el) | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| WO2002002113A1 (en) * | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| DK1381431T3 (da) | 2001-04-17 | 2007-10-08 | Ares Trading Sa | Aromatase-inhibition for at foröge implantationsrate |
| US7101573B2 (en) | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| WO2003082254A1 (en) | 2002-04-03 | 2003-10-09 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| WO2006114702A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| CN102335269B (zh) * | 2007-11-21 | 2013-06-19 | 客乐谐制药株式会社 | 芳香酶抑制剂 |
| RU2628808C2 (ru) * | 2011-09-08 | 2017-08-22 | Новартис Аг | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний |
-
2012
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en active Application Filing
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en active Application Filing
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118461T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν αναστολεα αρωματασης | |
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12014502778B1 (en) | Antibody formulation | |
| EP2958913A4 (en) | SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT | |
| GB2541835A (en) | Multivesicular liposome formulations of tranexamic acid | |
| MX2013008647A (es) | Metodo, composiciones y empaque para limpieza del intestino. | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
| MX391620B (es) | Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1). | |
| MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
| CL2012002893A1 (es) | Composición de al menos un ingrediente activo de origen vegetal o sintético análogo del mismo, o extracto de origen vegetal que lo contiene, en una solución acuosa, que además comprende lecitina como agente encapsulante; medicamento que la comprende; método para su preparación; y su uso para tratar parasitosis intestinales. | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| CY1115600T1 (el) | Πιπεραζινες ως ανθελονοσιακοι παραγοντες | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MY168692A (en) | The treatment of viral infections | |
| UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? | |
| EA201491477A1 (ru) | Фармацевтические составы, содержащие флупиртин | |
| CR20120465A (es) | Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente | |
| CR11588A (es) | Formulaciones farmacéuticas semisólidas | |
| MX383685B (es) | Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. | |
| TR201203084A2 (tr) | Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar. |